Controlling for the future
Edwards SAPIEN 3 Ultra TAVR facilitates future coronary access

You’re always thinking ahead. We can get behind that.
Your first-time valve choice today affects your patients’ treatment options tomorrow.

Up to 75% of severe aortic stenosis patients are at risk of developing CAD* requiring future coronary intervention.¹

Future intervention may be performed under limited TAVR experience.⁵

The design of the SAPIEN 3 valves is associated with favorable coronary access post-TAVR⁶ and post-TAVR-in-TAVR.⁷

Planning for future coronary access starts with Edwards SAPIEN 3 Ultra TAVR today

Prevalence of CAD in TAVR patients

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Age</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-Risk</td>
<td>73 yrs</td>
<td>27.7%</td>
</tr>
<tr>
<td>Intermediate-Risk</td>
<td>82 yrs</td>
<td>69.6%</td>
</tr>
<tr>
<td>High-Risk</td>
<td>84 yrs</td>
<td>74.9%</td>
</tr>
</tbody>
</table>

>60% of the population over the age of 65 live closer to a PCI-only center²

²Coronary Artery Disease

5. 2017 ACS Census Data, 2018 Medicare Quarterly SAF.

CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2021 Edwards Lifesciences Corporation. All rights reserved. PP--US-4357 v2.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com